{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Transplant recipients will be assessed for disease progression at 1 year after hematopoietic cell transplantation (HCT). The outcome is reported as the number of transplant recipients who experienced disease progression.","groups":[{"description":"TBI, single exposure on Day -1, 80 centigray (cGy) in addition to total lymphoid irradiation (TLI, 120 cGy/day for 9 days, weekends excluded) and anti-thymocyte globulin (ATG) 1.5 mg/kg (conditioning regimen)\n\nTotal body irradiation (TBI): Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning\n\nAnti-thymocyte globulin (ATG): Given intravenous (IV), Dose 1.5 mg/kg x 5 days\n\nTacrolimus: Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)\n\nMycophenolate mofetil (MMF): Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.\n\nTotal lymphoid irradiation (TLI): 9 x 120 cGy over 11 days","id":"OG000","title":"TBI+TLI"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"1 year","title":"Disease Progression","type":"SECONDARY","unitOfMeasure":"Participants"}